London, May 25, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Biologics Fill / Finish Services Market (2nd Edition) 2021 – 2030” report to its list of offerings. In pursuit of ...
Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service ...
The fill-finish market—a traditionally stable one—is increasingly adopting new technologies. Research from our 12th Annual Report and Survey of Biopharmaceutical Manufacturing, and other studies ...
SPOKANE, Wash.--(BUSINESS WIRE)--Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological ...
Automation, single-use systems, smaller footprints, and new drug delivery devices define trends for fill/finish outsourcing. Fill/finish operations have traditionally been among the most commonly ...
As medicines shift from one-size-fits-all treatments to personalized and small-batch drugs for rare diseases, the fill/finish industry is modernizing to address changing manufacturing needs. Parallel ...
Fill Finish Manufacturing Market worth $28.14 billion by 2030 with 8.9% CAGR | MarketsandMarkets(TM)
The MarketWatch News Department was not involved in the creation of this content. DELRAY BEACH, Fla., Aug. 19, 2025 /PRNewswire/ -- The global Fill Finish Manufacturing Market, valued at US$16.85 ...
DUBLIN--(BUSINESS WIRE)--The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service Offered, Type of FDF, ...
PCI Pharma, a Philadelphia-based CDMO, will spend $100 million to beef up aseptic liquid fill-finish manufacturing operations at its Bedford, New Hampshire, facility. The project follows PCI’s ...
New York, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Fill-Finish Manufacturing Market Report 2021-2031" - https://www ...
The development of genetically engineered drugs is a relatively new endeavor. Insulin, as Humulin® from Eli Lilly & Co. and approved in 1982, was the first genetically engineered biopharmaceutical.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback